Cellular dust provides new hope for regenerative medicine

While stem cells have the most therapeutic potential, the benefits of regenerative medicine may best be mobilised using extracellular vesicles (EVs), also known in the past as "cellular dust."

A team of researchers from CNRS, AP-HP, INSERM and Paris Descartes and Paris Diderot Universities have tested these vesicles for the first time in a porcine model for the treatment of post-operative digestive fistulas. Their results, which yielded a 100 percent success rate and appear in the 23 October 2018 edition of ACS Nano, open the door to testing in humans and broader possibilities for applications.

In the case of digestive fistula, in which there is abnormal communication between organs in the digestive tract or with the skin, regenerative medicine is an important therapeutic avenue to explore. Fistulas of this kind respond poorly to current treatments; they can develop following post-operative complications or an auto-immune disorders such as Crohn's disease, which causes digestive tract dysfunction.

For the first time, scientists at the Mati?res et syst?mes complexes Lab (CNRS/Université Paris Diderot), the Gastroenterology and Endoscopy Department at the Hôpital Européen Georges Pompidou (HEGP) AP-HP and the Laboratoire Imagerie de l'angiogén?se, plateforme d'imagerie du petit animal (INSERM/Université Paris Descartes/HEGP)1, used extracellular vesicles from stem cells to treat digestive fistula in a swine model. The study reveals that local injections into the fistula of a gel containing these vesicles results in the complete closure of post-operative digestive fistula.